The international surgical journal with global reach

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395: 1927-1936.

Published: 25th August 2020

Authors: The HALT-IT Trial Collaborators

Conclusion

Tranexamic acid did not reduce the rate of death from bleeding within five days, which was four per cent in both groups, in this study that included 12,009 patients. The rate of arterial thromboembolic events was similar in both groups, but venous thromboembolic events were more common with tranexamic acid: 0.8 versus 0.4 per cent, relative risk 1.15 to 2.98.

Pubmed Link